COVID-19 Solidarity Trial (WHO)
GPTKB entity
Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| https://www.w3.org/2000/01/rdf-schema#label |
COVID-19 Solidarity Trial (WHO)
|
| gptkbp:location |
global
|
| gptkbp:organizer |
gptkb:World_Health_Organization
|
| gptkbp:participants |
over 30 countries
|
| gptkbp:purpose |
evaluate potential treatments for COVID-19
|
| gptkbp:relatedTo |
gptkb:COVID-19_pandemic
|
| gptkbp:result |
no significant benefit found for tested drugs
|
| gptkbp:startDate |
2020
|
| gptkbp:status |
ongoing (as of 2023)
|
| gptkbp:studiedDrug |
gptkb:lopinavir/ritonavir
gptkb:remdesivir gptkb:interferon_beta-1a hydroxychloroquine |
| gptkbp:type |
gptkb:clinical_trial
|
| gptkbp:website |
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments
|
| gptkbp:bfsParent |
gptkb:John-Arne_Røttingen
|
| gptkbp:bfsLayer |
6
|